When we think about practices of European integration, we rarely think about how they may extend to outer space. Yet, a new global space race is in full swing, in which commercial and government actors worldwide are putting forward bold visions of human futures in outer space. Europe is at the cusp of deciding which role to play in this new space age. Do we witness the emergence of shared European visions for outer space, and how would these build on and inform current European integration practices? These questions are at the center of FUTURESPACE. They will be investigated using the joint European rocket Ariane as a case study. While Ariane was heralded as a symbol of European integration since its first launch in 1979, the rise of commercial companies like SpaceX has spurred profound debates about the future of the European Ariane program. My project will be unique in its attempt to expand questions of European integration to outer space by asking: Which kind of space futures are projected onto and realized through Ariane, and how do these futures relate to ideals and tensions of European integration? By exploring the intricate relations between large-scale technological projects, practices of European integration, and envisioned space futures, my project will provide empirically and theoretically rich insights into how the future of European integration in space is imagined and enacted in the global space race. Methodologically, FUTURESPACE conducts an interdisciplinary ethnography that links social science and engineering to better understand the material and imaginative aspects of this unique space infrastructure. With the increasing relevance of outer space for societies on Earth, such a project is much needed. FUTURESPACE will offer highly relevant and timely insights into how future visions of space shape forms of European collaboration in the present and how, conversely, geopolitical relations on Earth shape how, and by whom these futures are imagined.

Usage of therapeutic monoclonal antibodies (mAbs) has over the past 20 years become one of the most powerful pharmacological strategies in the treatment of various types of cancer, cardiovascular diseases and autoimmune disorders. Importantly, a central challenge in developing the required high protein concentration formulations of mAb therapeutics is the issue of protein solubility. The current approaches for addressing this challenge typically involve using different osmolyte excipients such as salts, carbohydrates, amino acids or surfactants, but they suffer from various problems including insufficient activity, low specificity, allergenic reactivity and others. Clearly, there exists an unmet need for novel strategies to increase the solubility of mAbs in pharmaceutical formulations in an efficient, cost-effective, target-specific manner. We propose to address this challenge by exploiting one of the central biological interaction partners of proteins, the RNA molecules. Specifically, we will: 1) bring to a product stage a computational software suite for designing short, weakly interacting RNA ligands (SWIRLs) that improve the solubility of aggregation-prone mAb therapeutics in a sequence- specific manner, and 2) commercialize the software for usage in a biopharmaceutical context. The designed SWIRLs increase the solubility of target proteins and shield them from unwanted aggregation through weak, specific interactions and a simultaneous alteration of solvent structure. Moreover, a major advantage of using short, standard unmodified RNAs is that they are non-immunogenic and are degradable in the blood, which makes them a unique material for formulation development. Importantly, the sequence-specific design of SWIRLs for a particular target protein will be based on fundamental physicochemical principles of RNA-protein interactions, recently elucidated by us in the context of our ERC Starting Independent grant project.

The complex pool of dissolved organic matter (DOM) in the oceans is almost exclusively accessible to diverse members of microbial community carrying out different types of metabolism thereby, affecting biogeochemical state of the ocean. To predict the response of the marine ecosystem to natural and anthropogenic perturbations, a mechanistic understanding on the relation between the organic matter (OM) field and the metabolic network operated by the microbial community needs to be refined. One largely overlooked, but significant source of DOM are jellyfish. Regardless the debate over the accuracy of their reported global increase and on the true cause of the observed jellyfish fluctuations, the increase in their population size can have serious ecological and socio-economic consequences. As jellyfish blooms decay, sinking carcasses represent large quantities of detrital OM (jelly-OM), rich in proteins and hence, a high quality substrate for the ambient bacterial community. However, the exact processes and mechanisms of bacterial jelly-OM degradation remain unknown. In the MIDAS project, an integrated interdisciplinary approach will be applied to characterize the composition of jelly-OM at the molecular level and the metabolic network operated by jelly-OM degrading bacterial communities using state-of-the-art analytical tools (ultra-high resolution mass spectrometry) and cutting edge –omics techniques combining emerging fields of marine metaproteomics and exoproteomics. This knowledge will enable us understanding the implications of jellyfish blooms on biogeochemical cycles in coastal seas.